Evidence map›Paper›PMID 31198981›Full record

ReviewInternational journal of molecular medicine2019

RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review).

Yuping Liu, Ting Liu, Tiantian Lei, Dingding Zhang, Suya Du, Lea Girani, Dandan Qi, Chen Lin, Rongsheng Tong, Yi Wang

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 1 synthesis or guideline pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Acetogenins fromACS omega · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Role of Necroptosis and Neuroinflammation in CSVD-Associated Cognitive Decline in db/db Mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yuping LiuHealth Management Center, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China.
Ting LiuSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, P.R. China.
Tiantian LeiSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, P.R. China.
Dingding ZhangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, P.R. China.
Suya DuDepartment of Clinical Pharmacy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, P.R. China.
Lea GiraniPersonalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China.
Dandan QiSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, P.R. China.
Chen LinSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, P.R. China.
Rongsheng TongPersonalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China.
Yi WangHealth Management Center, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China.
University of Electronic Science and Technology of China · CNSichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Necroptosis is a type of programmed cell death with necrotic morphology, occurring in a variety of biological processes, including inflammation, immune response, embryonic development and metabolic abnormalities. The current nomenclature defines necroptosis as cell death mediated by signal transduction from receptor‑interacting serine/threonine kinase (RIP) 1 to RIP3 (hereafter called RIP1/RIP3). However, RIP3‑dependent cell death would be a more precise definition of necroptosis. RIP3 is indispensable for necroptosis, while RIP1 is not consistently involved in the signal transduction. Notably, deletion of RIP1 even promotes RIP3‑mediated necroptosis under certain conditions. Necroptosis was previously thought as an alternate process of cell death in case of apoptosis inhibition. Currently, necroptosis is recognized to serve a pivotal role in regulating various physiological processes. Of note, it mediates a variety of human diseases, such as ischemic brain injury, immune system disorders and cancer. Targeting and inhibiting necroptosis, therefore, has the potential to be used for therapeutic purposes. To date, research has elucidated the suppression of RIP1/RIP3 via effective inhibitors and highlighted their potential application in disease therapy. The present review focused on the molecular mechanisms of RIP1/RIP3‑mediated necroptosis, explored the functions of RIP1/RIP3 in necroptosis, discussed their potential as a novel therapeutic target for disease therapy, and provided valuable suggestions for further study in this field.

Indexed as

Disease SusceptibilityMultifactorial InheritanceAnimalsBiomarkersGene Expression RegulationHumansMolecular Targeted TherapyNecroptosisNuclear Pore Complex ProteinsReceptor-Interacting Protein Serine-Threonine KinasesRNA-Binding ProteinsSignal TransductionStructure-Activity RelationshipAGFG1 protein, humanBiomarkersNuclear Pore Complex ProteinsReceptor-Interacting Protein Serine-Threonine KinasesRIPK3 protein, humanRNA-Binding Proteins

Identifiers

PMID31198981
PMCPMC6658002
OpenAlexW2950913401

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.